Abstract
This study examines the strategic choices of emerging firms seeking to capitalize on revolutionary technological change. These firms exhibit rapid and significant shifts in innovation priorities and pursue substantively different strategies in their attempts to exploit a common technological discontinuity. This analysis of new U.S. biotechnology firms reveals four distinct positioning strategies that reflect differences in research and development priorities, emphases on external collaboration, and the timing of strategic choices.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
